Impact of thyroid-stimulating hormone ratio change on the progression-free survival of patients receiving gemcitabine, cisplatin, and durvalumab therapy for advanced biliary tract cancer
Surgery Today · 2026-07 · 56 (7) · 1158-1168
DOI: 10.1007/s00595-025-03227-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Surgery Today, online erschienen am 05.01.2026. Verfasst von Michinori Matsumoto und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan. mmatsumoto4@jikei.ac.jp. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Thyrotropin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To investigate the independent predictors of progression-free survival (PFS) after gemcitabine, cisplatin, and durvalumab (GCD) therapy for advanced biliary tract cancer (BTC), including the thyroid-stimulating hormone (TSH) ratio pre- and post-GCD. METHODS: The subjects of this retrospective analysis were 29 patients receiving GCD for advanced BTC. The cutoff TSH ratios were determined by a receiver operating characteristic (ROC) curve for PFS. The independent predictors of PFS after GCD were determined by univariate and multivariate analyses. RESULTS: The median PFS was 4.9 (range, 0.9-16.8) months. The objective response and disease control rates were 13.0% and 52.2%, respectively. The cutoff values of the TSH ratio after one and two cycles were 0.97 [area under the ROC curve (AUROC): 0.86, 95% confidence interval (CI): 0.70-1.00], p = 0.02] and 1.2 (AUROC: 0.820, 95% CI: 0.664-0.976), respectively. Multivariate analysis identified pretreatment neutrophil-to-lymphocyte ratio (NLR) ≥ 5 [hazard ratio (HR): 6.27, 95% CI: 1.83-21.5, p = 0.004] and TSH ratio after two cycles of < 1.2 (HR: 3.25, 95% CI: 1.25-8.46, p = 0.02) as independent predictors of PFS. CONCLUSION: The TSH ratio after two GCD cycles of < 1.2 and a pretreatment NLR ≥ 5 are potential prognostic factors for poor PFS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan. mmatsumoto4@jikei.ac.jp.
- Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
- Department of Surgery, The Jikei University School of Medicine, 3-25-8 Nishi-shinbashi, Minato-ku, Tokyo, 105-8461, Japan.
Zitieren
APA
Matsumoto, M., Itoh, S., Tsunematsu, M., Yugawa, K., Furukawa, K., Haruki, K., Shirai, Y., Taniai, T., Yanagaki, M., Hamura, R., Uwagawa, T., Okui, N., Tanji, Y., Akaoka, M., Yoshizumi, T., & Ikegami, T. (2026). Impact of thyroid-stimulating hormone ratio change on the progression-free survival of patients receiving gemcitabine, cisplatin, and durvalumab therapy for advanced biliary tract cancer. Surgery Today, 56(7), 1158-1168. https://doi.org/10.1007/s00595-025-03227-3
Vancouver
Matsumoto M, Itoh S, Tsunematsu M, Yugawa K, Furukawa K, Haruki K, et al. Impact of thyroid-stimulating hormone ratio change on the progression-free survival of patients receiving gemcitabine, cisplatin, and durvalumab therapy for advanced biliary tract cancer. Surgery Today. 2026;56(7):1158-1168. doi:10.1007/s00595-025-03227-3
BibTeX
@article{Matsumoto2026,
author = {Matsumoto, Michinori and Itoh, Shinji and Tsunematsu, Masashi and Yugawa, Kyohei and Furukawa, Kenei and Haruki, Koichiro and Shirai, Yoshihiro and Taniai, Tomohiko and Yanagaki, Mitsuru and Hamura, Ryoga and Uwagawa, Tadashi and Okui, Norimitsu and Tanji, Yoshiaki and Akaoka, Munetoshi and Yoshizumi, Tomoharu and Ikegami, Toru},
title = {Impact of thyroid-stimulating hormone ratio change on the progression-free survival of patients receiving gemcitabine, cisplatin, and durvalumab therapy for advanced biliary tract cancer},
journal = {Surgery Today},
year = {2026},
volume = {56},
number = {7},
pages = {1158--1168},
doi = {10.1007/s00595-025-03227-3}
}
EUVIMED